erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
the financial times and its journalism are subject to a self-regulation regime under the ft editorial code of practice:.
stephen silberstein, md, director, jefferson university headache center..